{
    "clinical_study": {
        "@rank": "95740", 
        "arm_group": [
            {
                "arm_group_label": "NRX-1074, 1 mg", 
                "arm_group_type": "Experimental", 
                "description": "1 mg IV"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline"
            }, 
            {
                "arm_group_label": "NRX-1074, 5 mg", 
                "arm_group_type": "Experimental", 
                "description": "5 mg IV"
            }, 
            {
                "arm_group_label": "NRX-1074, 10 mg IV", 
                "arm_group_type": "Experimental", 
                "description": "10 mg"
            }, 
            {
                "arm_group_label": "NRX-1074, 50 mg IV", 
                "arm_group_type": "Experimental", 
                "description": "50 mg"
            }, 
            {
                "arm_group_label": "NRX-1074, 25 mg PO", 
                "arm_group_type": "Experimental", 
                "description": "25 mg"
            }, 
            {
                "arm_group_label": "NRX-1074, 125 mg PO", 
                "arm_group_type": "Experimental", 
                "description": "125 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the safety and tolerability of a single\n      intravenous (IV) and oral (PO) ascending dose of NRX-1074 as evidenced by the incidence and\n      severity of adverse events (AEs), changes in serum chemistry, hematology, and urinalysis,\n      changes in physical examination findings and subject-reported symptoms.\n\n      The secondary objectives of this study are to assess the plasma and cerebrospinal fluid\n      (CSF) pharmacokinetics (PK), the oral bioavailability of experimental formulations and the\n      renal elimination through urine concentration of NRX-1074 through 24 hours following dosing."
        }, 
        "brief_title": "Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female subjects\n\n          2. Aged 18 to 55 years\n\n          3. For female subjects, surgically sterile or at least 2 years menopausal, or using an\n             acceptable method of birth control from date of screening to at least 30 days after\n             the last dose of study drugIf of childbearing potential, have a documented negative\n             blood or urine pregnancy test within 24 hours prior to dosing.\n\n          4. Clinical laboratory values less than or equal to 2 times the upper limit of normal\n             (ULN) or deemed not clinically significant by the Investigator.\n\n          5. Ability to understand the requirements of the study, provide written informed\n             consent, abide by the study restrictions, and agree to return for the required\n             assessments.\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856556", 
            "org_study_id": "NRX1074-C-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "NRX-1074, 1 mg", 
                    "NRX-1074, 5 mg", 
                    "NRX-1074, 10 mg IV", 
                    "NRX-1074, 50 mg IV", 
                    "NRX-1074, 25 mg PO", 
                    "NRX-1074, 125 mg PO"
                ], 
                "description": "Single IV or PO administration", 
                "intervention_name": "NRX-1074", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single IV or PO placebo administration", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "safety", 
            "tolerability", 
            "pharmacokinetics"
        ], 
        "lastchanged_date": "November 27, 2013", 
        "location": {
            "contact": {
                "email": "anne@lotuscr.com", 
                "last_name": "Anne Arriaga", 
                "phone": "877-568-8727"
            }, 
            "facility": {
                "address": {
                    "city": "Pasadena", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91105"
                }, 
                "name": "Lotus Clinical Research"
            }, 
            "investigator": {
                "last_name": "Grace Ting, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Single Intravenous and Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Lotus Clinical Research", 
            "last_name": "Grace Ting, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Observed and laboratory-confirmed safety", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856556"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Plasma concentration of parent drug will be assessed over time to estimate duration of pharmacodynamics in future efficacy trials. Plasma concentration and pharmacokinetics will be related in time to observed side effects.", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "source": "Naurex, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Naurex, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}